Core Insights - Rani Therapeutics Holdings experienced a significant stock surge of 248% to close at $1.64 following a collaboration announcement with Chugai Pharmaceutical [1] - The stock has increased by 222% over the past month, primarily due to investor enthusiasm surrounding its RaniPill technology, which allows for oral delivery of biologic drugs [2] Collaboration Details - The partnership with Chugai Pharmaceutical aims to develop an oral formulation utilizing RaniPill technology and Chugai's rare disease antibody, with potential deal value exceeding $1 billion if all milestones are achieved [2][4] - Rani will receive an upfront payment of $10 million and is eligible for up to $75 million in technology transfer and development milestones [3] - Additional potential earnings include up to $100 million in sales milestones and single-digit royalties on future sales, with Chugai having the option to expand the partnership to include up to five additional drug targets [4] Financing and Investor Interest - Concurrently with the Chugai deal, Rani announced a $60.3 million private placement financing led by Samsara BioCapital, with participation from several notable investors [5] - Despite being classified as a penny stock, Rani has attracted attention from major institutional investors, including Vanguard Group and BlackRock, indicating a notable level of confidence in the company [5]